



11-15-08.

*[Handwritten signature]*

Docket No. 1151-4153US2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No.: 10/723,207 Confirmation No.: 8598  
Applicant(s): Chang Yi Wang Group Art Unit: 1644  
Examiner: Rooney, Nora Maureen  
Filed: November 24, 2003  
Customer No.: 27123  
For: PEPTIDE COMPOSITION AS IMMUNOGEN FOR TREATMENT OF ALLERGY

**EXPRESS MAIL CERTIFICATE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Express Mail Label No.: EV 825707750 US

Date of Deposit: November 13, 2006

I hereby certify that the following attached paper(s) and/or fee

1. Revised Amendment and Response Pursuant to 37 C.F.R. §1.115  
(12 sheets)
2. Return Postcard

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Albert Isles

(Typed or printed name of person mailing papers(s) and/or fee)


*[Handwritten signature]*  
\_\_\_\_\_  
(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.  
3 World Financial Center  
New York, NY 10281-2101  
(212) 415-8700 Telephone  
(212) 415-8701 Facsimile

27123

↑CUSTOMER NUMBER↑



Docket No. 1151-4153US2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Serial No.: 10/723,207 Confirmation 8598  
Applicant(s): Chang Yi WANG et al Group Art Unit: 1644  
Examiner: Nora M. Rooney, Esq.  
Filed: November 14, 2003 (Priority date: June 20, 1998)  
Customer No.: 27123

For: PEPTIDE COMPOSITION AS IMMUNOGEN FOR THE TREATMENT OF ALLERGY

Commissioner for Patents  
Washington, DC. 20231

**REVISED AMENDMENT AND RESPONSE**  
**PURSUANT TO 37 C.F.R. § 1.115**

Sir:

This paper is submitted in response to the Office Action issued November 6, 2006 for non-compliance. Entry and consideration of the amendment and response is respectfully requested.

**Amendment to the claims** are reflected in the listing of claims which begins on page 5 of this paper.

**Remarks** begin on page 7 of this paper.